1.21 USD
-0.01 (-0.82%)
Last: Feb 2, 2026, 11:40 AM
Taking everything into account, ERNA scores 2 out of 10 in our fundamental rating. ERNA was compared to 524 industry peers in the Biotechnology industry. ERNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ERNA is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year ERNA has reported negative net income.
- ERNA had a negative operating cash flow in the past year.
- In the past 5 years ERNA always reported negative net income.
- In the past 5 years ERNA always reported negative operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of -297.41%, ERNA is doing worse than 91.03% of the companies in the same industry.
- The Return On Equity of ERNA (-514.17%) is worse than 75.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -297.41% | ||
| ROE | -514.17% | ||
| ROIC | N/A |
ROA(3y)-333.38%
ROA(5y)-301.4%
ROE(3y)-1264.52%
ROE(5y)-959.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ERNA has a better Gross Margin (100.00%) than 99.24% of its industry peers.
- ERNA's Gross Margin has improved in the last couple of years.
- The Profit Margin and Operating Margin are not available for ERNA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 100% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
- ERNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for ERNA has been increased compared to 1 year ago.
- Compared to 5 years ago, ERNA has more shares outstanding
- There is no outstanding debt for ERNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- ERNA has an Altman-Z score of -58.23. This is a bad value and indicates that ERNA is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -58.23, ERNA is doing worse than 90.84% of the companies in the same industry.
- ERNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -58.23 |
ROIC/WACCN/A
WACC7.48%
2.3 Liquidity
- A Current Ratio of 1.58 indicates that ERNA should not have too much problems paying its short term obligations.
- ERNA's Current ratio of 1.58 is on the low side compared to the rest of the industry. ERNA is outperformed by 79.77% of its industry peers.
- A Quick Ratio of 1.58 indicates that ERNA should not have too much problems paying its short term obligations.
- ERNA's Quick ratio of 1.58 is on the low side compared to the rest of the industry. ERNA is outperformed by 78.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.58 | ||
| Quick Ratio | 1.58 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 95.77% over the past year.
- The Revenue for ERNA has decreased by -99.83% in the past year. This is quite bad
- ERNA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -50.61% yearly.
EPS 1Y (TTM)95.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.8%
Revenue 1Y (TTM)-99.83%
Revenue growth 3YN/A
Revenue growth 5Y-50.61%
Sales Q2Q%-100%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ERNA. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for ERNA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ERNEXA THERAPEUTICS INC / ERNA FAQ
Can you provide the ChartMill fundamental rating for ERNEXA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 2 / 10 to ERNA.
What is the valuation status for ERNA stock?
ChartMill assigns a valuation rating of 0 / 10 to ERNEXA THERAPEUTICS INC (ERNA). This can be considered as Overvalued.
How profitable is ERNEXA THERAPEUTICS INC (ERNA) stock?
ERNEXA THERAPEUTICS INC (ERNA) has a profitability rating of 1 / 10.
Can you provide the dividend sustainability for ERNA stock?
The dividend rating of ERNEXA THERAPEUTICS INC (ERNA) is 0 / 10 and the dividend payout ratio is 0.05%.